UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For Quarterly Period Ended March 31, 2021

 

or

 

[  ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Transition period from ______________to ______________

 

Commission File Number: 000-50099

 

GRAPEFRUIT USA, INC.

(Exact name of registrant as specified in its charter)

 

DELAWARE   95-4451059
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

1000 Northwest Street, Mid-Town Brandy Wine, Suite 1200-3094, Wilmington, DE 19801

(Address of principal executive offices) (Zip Code)

 

310-575-1175

Registrant’s telephone number, including area code

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of exchange on which registered
No par value common stock   GPFT   OTCQB

 

Securities registered pursuant to Section 12(g) of the Act:

 

Common Stock, $0.0001 par value

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes [X] No [  ]  

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes [X] No [  ]  

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One).

 

Large accelerated filer [  ] Accelerated filer [  ]  
Non-accelerated filer [  ] Smaller reporting company [X]  
(Do not check if a smaller reporting company)        

 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes [  ] No [X]  

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

 

As of May 24, 2021, the number of shares outstanding of the registrant’s class of common stock was 513,583,695.

 

 

 

     

 

 

TABLE OF CONTENTS

 

    Page
PART I. FINANCIAL INFORMATION  
Item 1. Condensed Financial Statements (Unaudited and Audited) 3
  Condensed Balance Sheets at March 31, 2021 (Unaudited) and December 31, 2020 (Audited) 3
  Condensed Statements of Operations for the Three Months Ended March 31, 2021 (Unaudited) and 2020 (Unaudited) 4
  Condensed Statements of Cash Flows for the Three Months Ended March 31, 2021 (Unaudited) and 2020 (Unaudited) 5
  Condensed Statement of Stockholders’ Deficit for the Three Months Ended March 31, 2021 (Unaudited) and 2020 (Unaudited) 6
  Notes to Condensed Financial Statements 7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 21
Item 3. Quantitative and Qualitative Disclosures About Market Risk 23
Item 4. Controls and Procedures 24
     
PART II. OTHER INFORMATION  
Item 1. Legal Proceedings 24
Item 1A. Risk Factors 25
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25
Item 3. Defaults Upon Senior Securities 25
Item 4. Mine Safety Disclosures 25
Item 5. Other Information 25
Item 6. Exhibits 25
     
SIGNATURES 26

 

  2  

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Condensed Financial Statements

 

GRAPEFRUIT USA, INC.

CONDENSED BALANCE SHEETS

 

 

March 31,

2021 

(Unaudited) 

 

December 31,

2020 

(Audited)

 
ASSETS            
             
CURRENT ASSETS:            
Cash $ 440,990   $ 299,895  
Accounts receivable   245,843     39,408  
Inventory   490,815     502,115  
Licensee agreement   57,200     63,800  
Other   17,774     43,644  
Total current assets   1,252,622     948,862  
NON-CURRENT ASSETS:            
Property, plant and equipment, net   1,798,823     1,790,930  
Operating right of use - assets   108,839     131,786  
Investment in hemp   169,950     169,950  
Other   7,459     7,459  
TOTAL ASSETS $ 3,337,693   $ 3,048,987  
             
LIABILITIES AND STOCKHOLDERS’ DEFICIT            
             
CURRENT LIABILITIES            
Notes payable $ 256,534   $ 256,436  
Accrued loan interest   893,087     758,107  
Related party payable   676,225     488,433  
Legal settlements - current portion   50,013     180,740  
Subscription payable   1,333,585     791,992  
Derivative liability   177,960     118,641  
Capital lease - current portion   65,810     67,071  
Operating right of use - liability - current portion   68,040     82,038  
Convertible notes - current portion   2,621,786     829,072  
Accounts payable and accrued expenses   771,820     807,051  
Total current liabilities   6,914,860     4,379,581  
             
Legal settlements - long-term   23,953     29,226  
Capital lease   24,519     38,835  
Operating right of use - liability   43,984     52,724  
Long-term notes payable, net   905,667     904,633  
Long-term convertible notes, net of discount   1,163,547     2,323,735  
Total long-term liabilities   2,161,670     3,349,153  
             
TOTAL LIABILITIES   9,076,530     7,728,734  
             
STOCKHOLDERS’ DEFICIT            
Common stock ($0.0001 par value, 1,000,000,000 shares authorized; 510,767,041 and 505,700,437 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively)   51,077     50,570  
Preferred stock ($0.0001 par value, 1,000,000 shares authorized; no shares issued and outstanding as of March 31, 2021 and December 31, 2020)   -     -  
Additional paid in capital   6,948,281     6,591,177  
Accumulated deficit   (12,738,195 )   (11,321,494 )
Total stockholders’ deficit   (5,738,837 )   (4,679,747 )
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 3,337,693   $ 3,048,987  

 

The accompanying notes are an integral part of these unaudited condensed financial statements

 

  3  

 

 

GRAPEFRUIT USA, INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

   

Three months

ended

   

Three months

ended

 
    March 31, 2021     March 31, 2020  
Revenues                
Bulk sales   $ 350,815     $ 393,559  
Total revenues     350,815       393,559  
Cost of goods sold     423,435       454,987  
Gross loss     (72,620 )     (61,428 )
Operating expenses:                
Sales     3,596       -  
General and administrative     401,412       302,559  
Total operating expenses     405,008       302,559  
                 
Loss from operations     (477,628 )     (363,987 )
Other income (expense):                
Interest expense     (421,381 )     (372,322 )
Change in value of derivative instruments     (59,319 )     (2,110,718 )
Gain (loss) on extinguishment of debt     (458,373 )     74,304  
Total other income (expense)     (939,073 )     (2,408,736 )
                 
Loss before income taxes     (1,416,701 )     (2,772,723 )
                 
Tax provision     -       -  
                 
Net loss   $ (1,416,701 )   $ (2,772,723 )
                 
Net loss per share - Basic and diluted   $ (0.00 )   $ (0.01 )
Weighted average common stock outstanding - Basic and diluted     508,357,473       394,315,293  

 

The accompanying notes are an integral part of these unaudited condensed financial statements

 

  4  

 

 

GRAPEFRUIT USA, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   

Three months

ended

   

Three months

ended

 
   

March 31,

2021

   

March 31,

2020

 
CASH FLOWS FROM OPERATING ACTIVITIES:                
Net loss   $ (1,416,701 )   $ (2,772,723 )
Adjustments to reconcile net loss to net cash used for operating activities:                
Depreciation and amortization expense     22,629       20,262  
Amortization of debt discount     237,226       202,979  
Change in value of derivative     59,319       2,110,718  
Loss on issuance of warranty     235,103       -  
Loss on extinguishment of debt     654,693       (74,304 )
Stock-based compensation for services     9,407       95,625  
Changes in operation assets and liabilities:                
Accounts Receivables     (206,435 )     (95,818 )
Inventory     11,299       11,228  
Prepaid expense and current assets     32,471          
Right-of-use assets     22,947          
Accounts payable     (35,231 )     58,420  
Other             5,000  
Accrued loan interest expense     134,980       85,290  
Right-of-use liability     (22,738 )        
Net cash (used for)/provided by used for operating activities     (261,031 )     (353,323 )
                 
CASH FLOWS FROM INVESTING ACTIVITIES:                
Purchase of land and equipment     (30,521 )     -  
Net cash used for investing activities     (30,521 )     -  
                 
CASH FLOWS FROM FINANCING ACTIVITIES:                
Principal repayment of capital lease liability     (15,577 )     (13,060 )
Repayment of legal liability     (136,000 )        
Proceeds from convertible notes, net     398,000       250,000  
Proceeds from (repayment of) loans, net     (1,568 )     (15,291 )
Proceeds from related parties     187,792          
Net cash proceeds from financing activities     432,647       221,649  
                 
NET INCREASE (DECREASE) IN CASH     141,095       (131,674 )
                 
CASH, BEGINNING BALANCE     299,895       266,607  
                 
CASH, ENDING BALANCE   $ 440,990     $ 134,933  
                 
SUPPLEMENTAL DISCLOSURE ON NON-CASH FINANCING ACTIVITY                
Cash paid for interest expense     32,667       185,820  
Debt converted to common stock     51,667       640,597  
Compensation paid through issuance of common stock     67,420       347,783  
Notes and accrued interest converted to common stock     -       79,754  
Reclassification of derivative liabilities to APIC     -       423,340  

 

The accompanying notes are an integral part of these unaudited condensed financial statements

 

  5  

 

 

GRAPEFRUIT USA, INC.

CONDENSED STATEMENT OF STOCKHOLDERS’ DEFICIT

(Unaudited)

 

    Common Stock     Additional           Total  
    Number of           Paid in     Accumulated     Stockholders’  
    Shares     Amount     Capital     Deficit     Deficit  
                               
Balance as of December 31, 2019     486,320,329     $ 48,632     $ 2,781,839     $ (7,264,498 )   $      (4,434,027 )
                                         
Shares issued for services     300,000       30       106,096       -       106,126  
                                         
Shares issued for settlement     7,213,933       721       565,572       -       566,293  
                                         
Net loss     -       -       -       (2,772,723 )     (2,772,723 )
                                         
Balance as of March 31, 2020     493,834,262     $ 49,383     $ 3,453,507     $ (10,037,221 )   $ (6,534,331 )
                                         
Balance as of December 31, 2020     505,700,437     $ 50,570     $ 6,591,177     $ (11,321,494 )   $ (4,679,747 )
                                         
Shares issued for services     1,399,937       140       55,804               55,944  
                                         
Shares issued for settlement     1,666,667       167       51,500               51,667  
                                         
Shares issued upon warrant exercise     2,000,000       200       249,800               250,000  
                                         
Net loss     -       -       -       (1,416,701 )     (1,416,701 )
                                         
Balance as of March 31, 2021     510,767,041     $ 51,077     $ 6,948,281     $ (12,738,195 )   $ (5,738,837 )

 

The accompanying notes are an integral part of these unaudited condensed financial statements

 

  6  

 

 

GRAPEFRUIT USA, INC.

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2021 AND 2020

 

NOTE 1 –ORGANIZATION AND NATURE OF OPERATIONS

 

Grapefruit USA, Inc (“we”, “our”, “us”, “GBI”, “Grapefruit”, or “the Company”) was formed as a California corporation on August 28, 2017 and began operating in September 2017.

 

On July 10, 2019, Grapefruit closed the Share Exchange after the completion of all conditions subsequent contemplated by the Share Exchange Agreement among the parties thereto ( “SEA”), by which Imaging3, Inc. (“IGNG”) was acquired in a reverse acquisition (the “Acquisition”) by the former shareholders of Grapefruit, the accounting acquirer. Under the terms of the SEA executed on May 31, 2019, IGNG became obligated to issue to Grapefruit’s existing shareholders that number of newly issued restricted IGNG common shares such that the former Grapefruit shareholders (now new IGNG shareholders) will own approximately 81% of the post-Acquisition IGNG common shares and the current IGNG shareholders will retain 19% of the post-Acquisition IGNG common shares. At the time of the execution of the SEA, IGNG had approximately 85,218,249 outstanding shares of common stock. Therefore, IGNG issued to Grapefruit’s shareholders 362,979,114 IGNG common shares to Grapefruit’s current shareholder on a pro rata basis with their then-current ownership of Grapefruit of which Bradley Yourist and Daniel J. Yourist own a combined 72.26%, or approximately 259,967,136 shares. Accordingly, the financial statements are prepared using the acquisition method of accounting with GBI as the accounting acquirer and IGNG treated as the legal acquirer and accounting acquiree. Because Imaging3, Inc. did not meet the accounting definition of an operating business, having only nominal assets, the reverse merger transaction was treated as a recapitalization and no goodwill was recognized.

 

  7  

 

 

The Company has applied for and received our provisional distribution renewal licensure which allows us to operate through May 13, 2021. Our annual manufacturing license has been renewed by the California Department of Health. Grapefruit has not yet applied for a license to cultivate and will not until construction has begun on our cultivation facility. We own two acres of fully entitled cannabis real property located in the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park. The location within Coachillin’ allows the Company to apply for and hold every cannabis license available under the California Cannabis laws.

 

We intend to buildout out the real property into a distribution, manufacturing and high-tech cultivation facility to facilitate our goal to become a seed to sale, fully vertically integrated Cannabis and CBD product Company. Grapefruit’s plans include an indoor 22,000 square foot multi-tiered canopy and adjoining tissue culture rooms.

 

We became members of the Indian Canyon and 18th Property Association on September 19, 2017 and have an ownership interest of 1.46% based upon the 77,156 gross parcel square foot of our property located in an approximately 5.3 million square foot facility. As of December 31, 2020, the common areas continue to be built throughout the entire canna-business park and are not complete.

 

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”).

 

The unaudited financial statements as of March 31, 2021 and December 31, 2020, and for the three months ended March 31, 2021 and March 31, 2020, have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information on the same basis as the annual financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. They do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes filed with the SEC for the year ended December 31, 2020.

 

Use of Estimates – The preparation of our financial statements in conformity with U.S. GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of our financial statements and the reported amounts of revenues and expenses during the periods presented.

 

We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term. The company’s most significant estimates related to useful life for depreciation, the value of long-lived assets and related impairment, and provision for income taxes of property and equipment.

 

Inventory – Inventory is comprised of raw material, work in process and finished goods. The following sets forth selected items from our inventory as of March 31, 2021 and December 31, 2020:

 

   

March 31,

2021

   

December 31,

2020

 
Raw material   $ 62,862     $ 16,891  
Work in process     13,144       23,566  
Finished goods     414,810       461,659  
    $ 490,816     $ 502,116  

 

  8  

 

 

We periodically review the value of our inventory and provide a write-down of inventory based on our assessment of the market conditions. Any write-down is charged to cost of goods sold.

 

Property, Plant and Equipment, net – Our property and equipment are recorded at cost. Assets held under capital leases are capitalized at the commencement of the lease at the lower of the present value of minimum lease payments at the inception of the lease or fair value. Maintenance and repairs are expensed as incurred. Depreciation is computed using the straight-line method over estimated useful lives of four to seven years, and amortization is computed using the straight-line method over the life of the applicable lease. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation are removed from our accounts and any resulting gain or loss is reflected in our consolidated statements of operations.

 

Land Improvements – Our land improvements are recorded at cost provided by our property association. These costs will continue to be capitalized until construction has been completed. Land improvements will not be depreciated after the construction has been completed by the property association.

 

Long-Lived Assets Impairment Assessment – Our long-lived assets are subject to an impairment test if there is an indicator of impairment. The carrying value and ultimate realization of these assets is dependent upon our estimates of future earnings and benefits that we expect to generate from their use. If our expectations of future results and cash flows are significantly diminished, other long-lived assets may be impaired and the resulting charge to operations may be material. When we determine that the carrying value of intangibles or other long-lived assets may not be recoverable based upon the existence of one or more indicators of impairment, we use the projected undiscounted cash flow method or realizable value to determine whether an impairment exists, and then measure the impairment using discounted cash flows.

 

Revenue Recognition – The Company derives revenues from the sale of product in accordance to ASC Topic 606. Revenues are recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods or services.

 

Revenue is recognized based on the following five step model:

 

  - Identification of the contract with a customer
  - Identification of the performance obligations in the contract
  - Determination of the transaction price
  - Allocation of the transaction price to the performance obligations in the contract
  - Recognition of revenue when, or as, the Company satisfies a performance obligation

 

Performance Obligations

 

Sales of products are recognized when all the following criteria are satisfied: (i) a contract with an end user exists which has commercial substance; (ii) it is probable the Company will collect the amount charged to the end user; and (iii) the Company has completed its performance obligation whereby the end user has obtained control of the product. A contract with commercial substance exists once the Company receives and accepts a purchase order or once it enters into a contract with an end user. If collectability is not probable, the sale is deferred and not recognized until collection is probable or payment is received. Control of products typically transfers when title and risk of ownership of the product has transferred to the customer. For contracts with multiple performance obligations, the Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. The Company uses an observable price to determine the stand-alone selling price for separate performance obligations or a cost-plus margin approach when one is not available. Historically the Company’s contracts have not had multiple performance obligations. The large majority of the Company’s performance obligations are recognized at a point in time related to the sale of products.

 

  9  

 

 

Cost of Goods Sold – Our cost of goods sold includes the costs directly attributable to revenue recognized and includes expenses related to the production, packaging and labelling of cannabis products; personnel-related costs, fees for third-party services, such as testing and transportation costs related to our distribution services.

 

Basic and Diluted Net Income Per Share – Basic net income per share is based upon the weighted average number of common shares outstanding. Diluted net income per share assumes that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. During 2019, potentially dilutive securities were excluded from the computation of weighted average shares outstanding-diluted because their effect was anti-dilutive.

 

    March 31, 2021    

December 31,

2020

 
Numerator:                
Net income attributable to common shareholders   $ (1,416,701 )     (4,229,851 )
Denominator:                
Weighted-average number of common shares outstanding during the period     508,357,473       498,230,051  
Dilutive effect of stock options, warrants, and convertible promissory notes     -       -  
Common stock and common stock equivalents used for diluted earnings per share   $ (0.00 )   $ (0.00 )

 

Derivative Financial Instruments - The Company generally does not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. The Company utilizes various types of financing to fund its business needs, including convertible notes and warrants and other instruments not indexed to our stock. The Company is required to record its derivative instruments at their fair value. Changes in the fair value of derivatives are recognized in earnings in accordance with ASC 815. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with warrants to purchase common stock and convertible notes.

 

Fair Value of Financial Instruments – We value our financial assets and liabilities using fair value measurements. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities measured at fair value are categorized based on whether the inputs are observable in the market and the degree that the inputs are observable. The categorization of financial instruments within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The hierarchy is prioritized into three levels (with Level 3 being the lowest) defined as follows:

 

Level 1: Quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.

 

Level 2: Observable inputs other than prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated with observable market data.

 

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies, and similar techniques that use significant unobservable inputs.

 

The carrying amount of our cash and cash equivalents approximates fair value because of the short-term nature of the instruments. The carrying amount of our notes payable at December 31, 2019, approximates their fair values based on comparable borrowing rates available to the company. The Company evaluated the fair market value of LVCA using Level 3 inputs. From that measurement, the Company recorded an impairment of LVCA.

 

  10  

 

 

There have been no changes in Level 1, Level 2, and Level 3 categorizations and no changes in valuation techniques for these assets or liabilities for the three months ended March 31, 2021 and year ended December 31, 2020.

 

    Level 1     Level 2     Level 3     Total  
Derivative Liabilities March 31, 2021   $ -     $ -     $ 118,641     $ 118,641  
Derivative Liabilities December 31, 2020   $      -     $      -     $ 118,641     $ 118,641  

 

Income Taxes – Income tax assets and liabilities are recorded using the asset and liability method. Under the asset and liability method, tax assets and liabilities are recognized for the tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as net operating loss and tax credit carryovers. Future tax assets and liabilities are measured using the enacted tax rates expected to apply when the asset is realized, or the liability settled. The effect on future tax assets and liabilities of a change in tax rates is recognized in income in the period that enactment occurs. To the extent that we do not consider it more likely than not that a future tax asset will be recovered, we will provide a valuation allowance against the excess.

 

We follow the provisions of ASC 740, Income Taxes. Because of ASC 740, we make a comprehensive review of our portfolio of tax positions in accordance with recognition standards established by ASC 740.

 

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

 

We have created our tax provision leveraging known tax court cases involving various marijuana dispensaries and other cannabis related businesses, including the section of the IRS Tax code of 280E. The U.S. Tax Code Section 280E is the federal statute that states that a business engaging in the trafficking of a Schedule I or II controlled substance, which includes cannabis and cannabis related products, are barred from taking the tax deductions or credits in their federal tax returns which are not considered as part of the business’ cost of goods sold. Given the guidance offered by the Tax code 280E we have prepared our tax provision according to this tax code.

 

Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations.

 

On December 22, 2017, the U.S. Tax Cuts and Jobs Act was enacted. U.S. tax reform introduced many changes, including lowering the U.S. corporate tax rate to 21 percent, changes in incentives, provisions to prevent U.S. base erosion and significant changes in the taxation of international income, including provisions which allow for the repatriation of foreign earnings without U.S. tax. The enactment of U.S. tax reform had no significant impact on our income taxes for the three months ended March 31, 2021 and 2020, respectively.

 

Research and Development Expenses – Research and development (“R&D”) costs are charged to expense as incurred. Our R&D expenses include, but are not limited to, consulting service fees and materials and supplies used in the development of our proprietary products and services.

 

General and Administrative Expenses – General and administrative expenses consist primarily of personnel-related costs, fees for professional and consulting services, travel costs, rent, bad debt expense, general corporate costs, and other costs of administration such as human resources, finance and administrative roles.

 

  11  

 

 

Commitments and Contingencies – Certain conditions may exist as of the date our financial statements are issued, which may result in a loss, but which will only be resolved when one or more future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

 

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, the estimated liability would be accrued in our consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

 

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.

 

Net Loss Per Share – We compute net loss per share in accordance with ASC 260, Earnings per Share. Under the provisions of ASC 260, basic net loss per share includes no dilution and is computed by dividing the net loss available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share takes into consideration shares of common stock outstanding (computed under basic net loss per share) and potentially dilutive securities that are not anti-dilutive.

 

Cash and Cash Equivalents – The Company considers all highly liquid investment securities with remaining maturities at the date of purchase of three months or less to be cash equivalents. Cash equivalents may be invested in money market funds, certificates of deposit or other interest-bearing accounts.

 

Concentration of Credit Risk – Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution may not be insured by the FDIC.

 

Accounts Receivable and Revenue – The accounts receivable balance was $ 245,843 as of March 31,2021 and $39,480 as of December 31, 2020. As the March 31, 2021, 75% of accounts receivable was split between two customers. In 2020, 99% of accounts receivable consisted of one customer. During the three months ended March 31, 2021, we diversified our customer base, but still have 30% of the revenues from one customer. For the three months ended March 31, 2020, 95% of the net revenues generated with one customer.

 

Recently Issued Accounting Pronouncements – From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of an Accounting Standards Update (“ASU”). Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on our condensed consolidated financial statements upon adoption.

 

Recently Issued Accounting Pronouncements Not Yet Adopted

 

Convertible Debt, and Derivatives and Hedging In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 will be effective for the Company in the first quarter of 2022. The Company is currently evaluating the amended guidance and the impact on its consolidated financial statements and related disclosures.

 

  12  

 

 

Recently Issued Accounting Pronouncements Adopted

 

Accounting for Income Taxes In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

 

Equity Securities, Equity-method Investments and Certain Derivatives In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

 

NOTE 3 – GOING CONCERN

 

Our consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the three months ended March 31, 2020, we incurred a net loss of $1,416,701, had a working capital deficit of $5,662,238 and had an accumulated deficit of $12,738,195 at March 31,2021. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations as they come due. There is no assurance that these events will be satisfactorily completed. As a result, there is doubt about our ability to continue as a going concern for one year from the issuance date of these financial statements

 

Management’s plan regarding this matter is to, amongst other things, seek additional equity financing by selling our equity securities and obtaining funds through the issuance of debt. We cannot be certain that funds from these sources will be available when needed or, if available, will be on terms favorable to us or to our stockholders. If we raise additional funds or settle liabilities by issuing equity securities, the percentage ownership of our stockholders may be reduced, stockholders may experience additional dilution, or such equity securities may provide for rights, preferences and/or privileges senior to those of the holders of our common stock. Our ability to execute our business plan and continue as a going concern may be adversely affected if we are unable to raise additional capital or operate profitably.

 

On May 31, 2019, the Company executed the Stock Purchase Agreement (“SPA”) with Auctus pursuant to the terms of which the Company agreed to sell $4,000,000 of the Notes and issue $6,200,000 of callable warrants (the “Warrants” and, together with the Notes, the “Securities”) to Auctus. Auctus is the Selling Security Holder. In addition, on May 31, 2019, we also entered into a registration rights agreement with Auctus (the “Registration Rights Agreement”) whereby we are obligated to file a registration statement to register the resale of the shares underlying the Securities. On July 25, 2019 (as amended on January 17, 2020), a registration statement was filed to comply with the Registration Rights Agreement . Pursuant to the SPA, Auctus became obligated to purchase the $4,000,000 of Notes from Grapefruit in four tranches as follows: $600,000 at the SPA closing, which was funded on June 6, 2019; the second tranche of $1,422,750 on the day IGNG filed the registration statement, which was funded on August 16, 2019; the third tranche of $1,030,000 was funded the day the SEC declares the registration statement effective and the fourth tranche of $1 million was funded 90 days after effectiveness. As of December 31, 2020, all tranches of this financing were completed. The Company has received gross proceeds of $4,052,750.

 

In the first quarter of 2021, Auctus exercised 2,000,000 warrants at $0.125, for proceeds to the Company of $250,000 and issued a $450,000 convertible note to Auctus.

 

  13  

 

 

NOTE 4 – RIGHT OF USE ASSET AND LIABILITY

 

During 2018 we reviewed various facilities and identified a suitable, compliant cannabis facility located in the city of Dessert Hot Springs, to build our manufacturing and distribution facility. This commercial park is owned and operated by Coachillin’ Holding LLC and we purchased land rights from Coachillin’ Holding LLC on December 21, 2017 to secure our specific location within their commercial park.

 

Construction of our facility has not been completed, and we have been provided an estimated completion date of September 2022. In order for us to obtain California cannabis licensing from state and local officials we entered into an operating lease with Coachillin’ Holdings to temporarily occupy an area near the location of our permanent location within the Coachillin’ commercial park.

 

We entered into this operating land lease agreement with Coachillin’ Holdings LLC on September 1, 2018 to rent approximately 2,268 square feet of leasable land area. The operating lease renews annually and has a base rent of $0.50 square foot of leasable area of the designated premise assigned by Coachillin’ Holdings LLC. We paid an initial non-refundable prepaid rent of $3,402 which was expensed during the three months following the signed agreement, and we will continue to pay $1,134 monthly. We entered into this operating agreement in order to obtain our provisional cannabis licenses for manufacturing and distribution during 2020.

 

The Company entered into a 36-month lease agreement for office space in July 2019 at $6,963 a month, with an approximate 2% increase annually.

 

The Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable. The Company used an estimated incremental borrowing rate of 6% to estimate the present value of the right of use liability.

 

The Company has right-of-use assets of $108,839, right-of-use liability of $112,025 as of March 31, 2021. Operating lease expense for the three months ended March 31, 2020 was $24,932.

 

The following table provides the maturities of lease liabilities at March 31, 2021:

 

Maturity of Lease Liabilities      
2021     71,748  
2022     44,756  
2023     -  
2024     -  
2025        
2026 and thereafter     -  
Total future undiscounted lease payments     116,504  
Less: Interest     (4,479 )
Present value of lease liabilities   $ 112,025  

 

  14  

 

 

NOTE 5 – INVENTORY

 

At March 31, 2021 and December 31, 2020, our inventory was, as follows:

 

   

March 31,

2021

   

December 31,

2020

 
Raw material   $ 62,862     $ 16,891  
Work in process     13,144       23,566  
Finished goods     414,810       461,659  
    $ 490,816     $ 502,116  

 

We periodically review the value of our inventory and provide a write-down of inventory based on our assessment of the market conditions. Any write-down is charged to cost of goods sold.

 

NOTE 6 – PROPERTY, PLANT AND EQUIPMENT, NET

 

Property, plant and equipment, net of accumulated depreciation and amortization, at March 31, 2021 and December 31, 2020 was as follows:

 

    March 31, 2021     December 31, 2020  
Vehicle   $ 41,142     $ 41,142  
Extraction equipment     296,748       287,028  
Extraction laboratory     126,707       126,707  
Warehouse facility     50,158       50,158  
Land and land improvement/development     1,476,996       1,456,194  
Accumulated depreciation and amortization     (192,928 )     (170,299 )
Property, plant and equipment   $ 1,798,823     $ 1,790,930  

 

The Company acquired the extraction equipment, laboratory, and warehouse facility during 2018 and 2019 and made preparations and final testing for future production. Final preparations for certain extraction and warehouse work were completed, and these related assets were placed in service on April 1, 2019, at which time we commenced depreciating this asset.

 

The amount of related depreciation expense for the three months ended March 31, 2021 and 2020 is $22,629 and $19,622, respectively.

 

NOTE 7 – CAPITAL LEASE PAYABLE

 

Capital lease payable consists a capital lease agreement entered into in April 2018 to finance the purchase of various lab and manufacturing equipment. The outstanding balance on the 48-month installment capital lease was $148,511 and $161,570 as of March 31, 2021 and December 31, 2020, respectively. The terms of the 48-month capital lease specify monthly payments of $4,575. The interest rate implicit in the lease is about 15% and the maturity date is February 2022.

 

In addition, the Company entered into additional 48-month leases in May 2019 for production facilities and storage of product. Monthly payments for the facility and storage totals $1,935.

 

  15  

 

 

A summary of minimum lease payments on capital lease payable for future years is as follows:

 

    March 31, 2021  
Remainder 2021   $ 58,590  
2022     32,337  
2023     7,740  
2024     -  
2025     -  
Thereafter     -  
Total minimum lease payments     98,667  
Less: amount representing interest     (8,338 )
Capital lease liability   $ 90,329  

 

NOTE 8 – NOTES PAYABLE

 

In October 2017, in connection with our purchase of two acres of fully entitled cannabis real property located in the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park, the Company issued a first and second trust deed note in the amounts of $700,000 and $200,000, respectively. The first and second trust deed notes are long-term notes and are interest only notes, at 13.0%, and mature in August 2022, with the principal payment due at maturity. For the $700,000 loan, the monthly payment is approximately $7,500. For the $200,000 loan, the monthly payment is approximately $2,200. The 1st and 2nd trust deeds are secured by the land as well as property owned by two officers of the company and three other related parties. Also, each party has personally guaranteed or pledged additional collateral. The notes include a debt discount as of March 31, 2021 of $30,600.

 

In April 2018, the Company issued a note due 60 days after funding with a principal amount of $250,000 and interest totaling $125,000. As of March 31, 2021, the note has not been repaid and was amended to carry an additional 10% interest rate of the total balance due, Accrued interest for this loan totals $190,625. The note is past due. Two officers of the Company have personally guaranteed the loan.

 

In September 2019, the Company issued another note of $102,569 to an unrelated party with 5% interest, which was repaid in full on October 20, 2020.

 

NOTE 9 – CONVERTIBLE NOTES PAYABLE

 

In August 2020, 9,100,380 shares were issued to settle $80,754 debt of a note and accrued interest resulting in a loss of $5,225.

 

Amortization of note discounts, which is included in interest expense, amounted to $353,811 during the three months ended March 31, 2021 and $278,204 for the three months ended March 31, 2020.

 

Grapefruit acquired convertible notes in its acquisition of Imaging3, Inc. on July 10, 2019. (See Note 15.) On May 31, 2019, the Company executed the SPA with Auctus pursuant to the terms of which the Company agreed to sell $4,000,000 of the Notes and issue $6,200,000 of callable warrants (the “Warrants” and, together with the Notes, the “Securities”) to Auctus. Auctus is the Selling Security Holder. In addition, on May 31, 2019, we also entered into a registration rights agreement with Auctus (the “Registration Rights Agreement”) whereby we are obligated to file a registration statement to register the resale of the shares underlying the Securities. On July 25, 2019 (as amended on January 17, 2020), a registration statement was filed to comply with the Registration Rights Agreement . Pursuant to the SPA, Auctus became obligated to purchase the $4,000,000 of Notes from Grapefruit in four tranches as follows: $600,000 at the SPA closing, which was funded on June 6, 2019; the second tranche of $1,422,750 on the day IGNG filed the registration statement, which was funded on August 16, 2019; the third tranche of $1,030,000 was funded the day the SEC declares the registration statement effective and the fourth tranche of $1 million was funded 90 days after effectiveness. As of December 31, 2020, all tranches of this financing were completed. The Company has received gross proceeds of $4,052,750. The Notes have a two-year term and will bear interest at 10%.

 

  16  

 

 

On April 15, 2021, the company renegotiated the debt agreement related to these notes modifying the convertible notes conversion price from a variable rate to a fixed rate conversion price with an effective date of December 31, 2020. As a result of the agreement, the Company recorded a noncash expense for the change in the value of derivative instruments of $40,372,883, which was simultaneously offset by a noncash gain of $39,640,477 from the extinguishment of debt, resulting a net loss of $753,699 from the renegotiation of the debt.

 

On February 26, 2021, the company issued a $450,000 convertible to Auctus bearing 12% interest and 1-year maturity date. Principal payments shall be made in six (6) installments each in the amount of $75,000 commencing one hundred and eighty (180) days following the Issue Date and continuing thereafter each thirty (30) days for six (6) months. Notwithstanding the forgoing, the final payment of Principal and Interest shall be due on the Maturity Date. The conversion price set at $0.075.

 

In addition, the Company has eleven other convertible notes comprising $296,000 outstanding and they are currently in default. The interest on these notes varies from 5-10%. As of March 12, 2021, we are in the process of converting eight of the notes amounting to $241,000.

 

NOTE 10 – NOTES PAYABLE, RELATED PARTY NOTES PAYABLES, AND OPERATING LEASE – RELATED PARTY

 

Notes payable to officers and directors as of March 31, 2021 and December 31, 2020 are due on demand and consisted of the following:

 

    March 31, 2021     December 31, 2020  
Payable to an officer and director   $ 82,056     $ 82,056  
Payable to an individual affiliate of an officer and director     40,000       40,000  
Payable to a company affiliate to an officer and director     554,169       366,377  
    $ 676,225     $ 488,433  

 

Notes payables bear interest at 10%.

 

A related party leased two eco-pods in April 2019 and May 2019, which are refurbished shipping containers, located on this specific parcel within Coachillin’. The lease is treated as an operating lease and payment responsibility is ultimately the responsibility of the related party. The Company assumed these lease payment obligations in May 2019. The monthly payments are $1,055 and $880, for the duration of the lease terms of four and five years, respectively.

 

NOTE 11 – EQUITY

 

Preferred Stock

 

The Company has authorized 1,000,000 shares of $0.0001 par value preferred stock. As of March 31, 2021, and December 31, 2020, there are no shares of preferred stock outstanding.

 

Common Stock

 

The Company is authorized to issue 1,000,000,000 shares of $0.0001 par value common stock.

 

During the three months ended March 31, 2021 the Company issued a total of 1,399,937 shares were issued for services rendered valued at $55,945; 1,666,667 shares were issued related to for a settlement valued at $51,667; and 2,000,000 shares were issued for warrant exercised at $0.125.

 

  17  

 

 

As of March 31, 2021, there were approximately 613 record holders of our common stock, not including shares held in “street name” in brokerage accounts which is unknown. As of March 31, 2021, there were 510,767,041 shares of our common stock outstanding on record.

 

Stock Option Plan

 

During 2014, the Board of Directors adopted, and the shareholders approved, the 2014 Stock Option Plan under which a total of 1,811,401 shares of common stock had been reserved for issuance. The 2014 Stock Option Plan will terminate in September 2024.

 

Stock Options

 

As of March 31, 2021, employees of the Company hold options to purchase 250,000 shares of common stock at an exercise price of $1.00.

 

Transactions in FY 2021   Quantity    

Weighted-

Average

Exercise Price

Per Share

   

Weighted-

Average

Remaining

Contractual Life

 
Outstanding, December 31, 2020     250,000     $ 1.00       4.57  
Granted                        
Exercised     -                  
Cancelled/Forfeited     -                  
Outstanding, March 31, 2021     250,000     $ 1.00       4.32  
Exercisable, March 31, 2021     250,000     $ 1.00       4.32  

 

The weighted average remaining contractual life of options outstanding issued under the Plan was 4.32 years at March 31, 2021.

 

NOTE 12 — WARRANTS

 

Following is a summary of warrants outstanding at March 31, 2021:

 

Number of Warrants   Exercise Price     Expiration Date
2,250,000   $ 0.20     July 2023
37,500   $ 0.10     April 2022
500,00   $ 0.10     August 2022
575,000   $ 0.10     April 2023
125,000   $ 0.10     May 2023
162,500   $ 0.10     August 2023
2,800,000   $ 0.40     May 2022
302,776   $ 0.10     January 2024
12,000,000   $ 0.10     March 2021
2,160,000   $ 0.10     June 2021
14,000,000   $ 0.125     May 2021
15,000,000   $ 0.15     May 2021
8,000,000   $ 0.25     May 2021

 

Grapefruit recorded warrants to issue common stock upon exercise in its acquisition of Imaging3, Inc. on July 10, 2019. (See Note 15.) As part of the SEA, the Company also issued 16,000,000 warrants to purchase 16,000,000 shares of the Company’s common stock at an exercise price of $0.125 per share, 15,000,000 warrants to purchase 15,000,000 shares of the Company’s common stock at an exercise price of $0.15 per share, 8,000,000 warrants to purchase 8,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share for a period of two year from the date of issuance.

 

  18  

 

 

In addition to the Notes in connection with the SPA agreement, IGNG issued to the Investor a warrant to purchase 16,000,000 shares of its common stock at $0.125 per share, a warrant to purchase 15,000,000 shares at $0.15 per share and a warrant to purchase 8,000,000 shares at $0.25 per share (collectively, the “Warrants”). The Warrants are “cash only” and are callable if IGNG stock trades on the OTCQB at 200% or more of a given exercise price for 5 consecutive days.

 

On February 26, 2021, 2,250,000 warrants were issue with an exercise price of $0.20 in relation to the convertible note (See Note 9 Convertible note payable). On April 15, 2021 as part of the renegotiated terms of the convertible notes, 20,000,000 additional warrants were issued at an exercise price of $0.075.

 

NOTE 13 — DERIVATIVE LIABILITIES

 

Grapefruit recorded derivative instruments in its acquisition of Imaging3, Inc. on July 10, 2019. (See Note 15.) The Company’s only asset or liability measured at fair value on a recurring basis was its derivative liability associated with related warrants to purchase common stock and the conversion features embedded in convertible promissory notes.

 

In connection with financing transactions, the Company issued warrants to purchase common stock and convertible promissory notes. These instruments included provisions that could result in a reduced exercise price based on specified full-ratchet anti-dilution provisions. The “reset” provisions were triggered in the event the Company subsequently issued common stock, stock warrants, stock options or convertible debt with a stock price, exercise price or conversion price lower than contractually specified amounts. Upon triggering the “reset” provisions, the exercise / conversion price of the instrument will be reduced. Accordingly, pursuant to ASC 815, these instruments were not considered to be solely indexed to the Company’s own stock and were not afforded equity treatment.

 

On April 15, 2021, the company renegotiated conversion terms on $4,502,750 of convertible notes with Auctus. All variable conversion prices were replaced with a fixed conversion price of $0.075. In addition, the Company issued an additional 20,000,000 warrants with an exercise price of $0.075 per share.

 

The following table summarizes activity in the Company’s derivative liability during the three-month period ended March 31, 2021:

 

12-31-20 Balance   $ 118,641  
Creation/acquisition     -  
Reclassification of equity   -  
Change in Value     59,319  
3-31-21Balance   $ 177,960  

 

The Company classifies the fair value of these derivative liabilities under level 3 of the fair value hierarchy of financial instruments. The fair value of the derivative liability was calculated using a Black Scholes model. The Company’s stock price and estimates of volatility are the most sensitive inputs in validation of assets and liabilities at fair value. The liabilities were measured using the following assumptions:

 

Term   1-3 years  
Dividend Yield     0 %
Risk-free rate     0.07% - 0.16 %
Volatility     167 %

 

  19  

 

 

NOTE 14 – INVESTMENTS

 

Investment in Hemp

 

In September 2019, the Company invested in hemp product that was purchased and stored by a third party. The Company expects to sell the product by the third quarter of 2021.

 

NOTE 15 – COMMITMENTS AND CONTINGENCIES

 

Alpha Capital Anstalt and Brio Capital Master Fund, LTD

 

On September 13, 2017, Alpha Capital Anstalt and Brio Capital Master Fund, LTD, two minority members of a group of investors in the Company (the “Plaintiff”) filed a lawsuit seeking damages and injunctive relief in the United States District Court for the Southern District of New York claiming that the Company breached certain Note and Warrant agreements among the parties to the action. The holders of the majority of the investment involved in the above lawsuit chose not to join in the lawsuit and have informed the Company that they believe the lawsuit to be baseless. On November 21, 2017, the Court denied the Plaintiff’s request for injunctive relief against the Company. As a result, the case essentially became an action for money damages against the Company, which the Company believed to be without merit and defended vigorously. However, on July 27, 2018 United States District Court for the Southern District of New York granted the plaintiffs motion for summary judgement, awarding them approximately $1.4 million dollars. On April 15, 2019 the Company executed a settlement agreement (the “Settlement Agreement”) with the defendants to settle the matter by agreeing to pay the defendants an aggregate of $200,000 and issuing them an aggregate of 7,705,698 of the Company’s common shares (subject to certain possible adjustments to the amount of shares to be issued to the Defendants by the Company). The Company paid this $200,000 to the defendants and issued the 7,705,698 shares to the defendants in the fourth quarter of 2019. Subsequently, the defendant’s claimed the aforementioned share adjustment had been triggered and made a demand that the Company issue additional shares pursuant to the terms of the Settlement. In April 2021, the Company issued an additional aggregate of 2,822,654 shares the Company’s stock to these defendants in final settlement of the dispute.

 

Galileo Surgery Center LP/Cypress Ambulatory Surgery Center LP vs Imaging3, Inc. Settlement

 

The Company came to a settlement with Galileo Surgery Center LP/Cypress Ambulatory Surgery Center LP (“Galileo”) for $75,572 with an interest rate of 10%, requiring payments of $2,000 per month beginning in August 2019 until paid in full. The company is currently behind on payments.

 

NOTE 16 – SUBSEQUENT EVENTS

 

On April 15, 2021, the company renegotiated conversion terms on $4,502,750 of convertible notes with Auctus. All variable conversion prices were replaced with a fixed conversion price of $0.075. In addition, the Company issued an additional 20,000,000 warrants with an exercise price of $0.075 per share.

 

On April 19, 2021, Alpha Capital Anstalt and Brio Capital Master Fund, LTD were issued 2,822,654 shares pursuant to the true-up provision in their settlement (See Note 15 Commitments and Contingencies).

 

In May 2021, 3,920,865 shares were issued to Greenberg Glusker Fields Claman & Machtinger LLP pursuant to the make-whole provision (See Note 15 Commitments and Contingencies).

 

  20  

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Statements

 

This Form 10-Q contains financial projections and other “forward-looking statements,” as that term is used in federal securities laws, about Grapefruit’s financial condition, results of operations and business. These statements include, among others, statements concerning the potential for revenues and expenses and other matters that are not historical facts. These statements may be made expressly in this Form 10-K. You can find many of these statements by looking for words such as “believes,” “expects,” “anticipates,” “estimates,” or similar expressions used in this Form 10-K. These forward-looking statements are subject to numerous assumptions, risks and uncertainties that may cause our actual results to be materially different from any future results expressed or implied by us in those statements. The most important facts that could prevent us from achieving our stated goals include, but are not limited to, the following:

 

  (a) volatility or decline of our stock price;
     
  (b) potential fluctuation in quarterly results;
     
  (c) our failure to earn revenues or profits;
     
  (d) inadequate capital to continue the business and barriers to raising the additional capital or to obtaining the financing needed to implement our business plans;
     
  (e) failure to make sales;
     
  (f) changes in demand for our products and services;
     
  (g) rapid and significant changes in markets;
     
  (h) litigation with or legal claims and allegations by outside parties, causing us to incur substantial losses and expenses;
     
  (i) insufficient revenues to cover operating costs;
     
  (j) dilution in the ownership of the Company through the issuance by us of additional securities and the conversion of outstanding warrants, notes and other securities;

 

We cannot assure that we will be profitable. We may not be able to develop, manage or market our products and services successfully. We may not be able to attract or retain qualified executives and technology personnel. We may not be able to obtain customers for our products or services. Our products and services may become obsolete. Government regulation may hinder our business. Additional dilution in outstanding stock ownership will be incurred due to the issuance or exercise of more shares, warrants and other convertible securities.

 

Because the statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by the forward-looking statements. We caution you not to place undue reliance on the statements, which speak only as of the date of this Form 10-Q. The cautionary statements contained or referred to in this section should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may make. We do not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events.

 

The following discussion should be read in conjunction with our financial statements and notes to those statements. In addition to historical information, the following discussion and other parts of this annual report contain forward-looking information that involves risks and uncertainties.

 

  21  

 

 

Results of Operations for the Three Months Ended March 31, 2021 as compared to the Three Months Ended March 31, 2020.

 

The following sets forth selected items from our statements of operations for three months ended March 31, 2021 and for the three months ended March 31, 2020.

 

   

Three Months

Ended

   

Three Months

Ended

 
   

March 31,

2021

   

March 31,

2020

 
Net revenues   $ 350,815     $ 393,559  
Cost of goods sold     423,435       454,987  
Gross loss     (72,620 )     (61,428 )
Sales expense     3,596       -  
General and administrative expense     401,412       302,559  
Loss from operations     (477,628 )     (363,987 )
Change in value of derivatives     (59,319 )     (2,110,718 )
Interest and other income (expense)     (879,754 )     (298,018 )
Net loss   $ (1,416,701 )   $ (2,772,723 )

 

Revenue for the three months ended March 31, 2021 was $350,815 compared to $393,559 for the corresponding period in 2020, a decrease of $42,744 or 10.8%. This decrease in revenue is primarily due to the fact that there was a very strong cannabis crop in the last quarter of 2020, which drove down wholesale cannabis prices significantly and limited the profitability of our distribution and trading operations. The Company expects such cyclical revenue deviations to be mitigated in 2021 and following years by a significant growth of revenue from our HourGlass products, which will be unaffected by these cyclical events.

 

Cost of goods sold for the three months ended March 31, 2021 was $423,435 as compared to $454,987 for the corresponding period in 2020, a decrease of $29,602, or 6.5%. Included in cost of goods sold the three months ended March 31, 2021 and 2020 are plant operation and other direct overhead expenses incurred to maintain our production facilities. These fixed carrying costs affect our gross margin more significantly at lower revenues than at our anticipated full operating activity levels. Consequently, we expect our gross margins to significantly improve during 2021 as sales increase.

 

Our resulting gross loss for the three months ended March 31, 2021 was $72,620 as compared with $61,428 for the corresponding period in 2020, an increase of $13,442, or 22.7%.

 

General and administrative expenses for the three months ended March 31, 2021 were $401,412 compared to $302,559 for 2020, an increase of $101,627, or 32.3%. The increase in costs was primarily due to an increase in legal expenses.

 

Our resulting net loss from operations for the three months ended March 31, 2021 was $477,628 as compared to $363,987 for the corresponding period for 2020, an increase of $115,068, or 31.7%.

 

  22  

 

 

As part of the reverse merger in July 2019, the Company recorded derivative liabilities substantially in the form of convertible notes and related warrants with variable conversion features. On April 15, 2021, the company renegotiated the debt agreement with the lender modifying the convertible notes conversion price from a variable rate to a fixed rate conversion price for $4,502,750 of convertible notes, with an effective date of December 31, 2020. Change in value of derivatives, a non-cash expense, for the three months ended March 31, 2021, was $59,319 as compared to $2,110,718 for the corresponding period for 2020.

 

Included in interest and other expense for the three months ended March 31, 2021, is a non-cash expense of $513,267 related to shares issued as part of a make-whole agreement (see Note 15 Commitments and contingencies).

 

Our resulting net loss for the three months ended March 31, 2021 was $1,416,701 as compared to $2,772,723 for the corresponding period for 2020, a decrease of $1,356,022, or 48.9%.

 

COVID-19 Impact

 

Our business and operating results for 2020 was impacted by the COVID-19 pandemic. However, we have seen improvement in our business, which we expect to continue throughout 2021.

 

Liquidity and Capital Resources

 

Our cash position increased to $440,990 as of March 31, 2021 from $299,895 as of December 31, 2020. The increase in cash was primarily due to the issuance of debt offset by operating activities. Our total current assets increased to $1,252,622 as of March 31, 2021, from $948,862 as of December 31, 2020.

 

Our total current liabilities increased to $6,914,860 as of March 31, 2021 from $4,379,581 as of December 31, 2020. This increase is primarily due to convertible note’s nearing maturity dates.

 

During the three months ended March 31, 2021, we used $261,031 of net cash for operating activities, as compared to cash used by operations of $353,323 used during the three months ended March 31, 2020. Net cash used in investing activities during the three months ended March 31, 2021 was $30,521, as compared to $0 during the three months ended March 31, 2020. Net cash provided by financing activities during the three months ended March 31, 2021 was $432,647, as compared to $221,649 during the three months ended March 31, 2020.

 

We expect our working capital requirements in the next year to be met primarily by the proceeds of issuance of debt, equity and other securities to our existing creditor, shareholders, and other investors, as well as from cash flow from operations. We also expect that, as in the past, significant amounts of our convertible debt with a major lender will be converted into equity. We expect to need additional working capital from outside sources to cover our anticipated operating expenses. There is no assurance that the Company will be able to raise sufficient additional capital or financing to continue in business or to effectively execute its business plan.

 

Going Concern Qualification

 

Our consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the three months ended March 31, 2021, we incurred a net loss of $1,416,701, had a working capital deficit of $5,662,238 and had an accumulated deficit of $12,738,195 at March 31, 2021. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations as they come due. There is no assurance that these events will be satisfactorily completed. As a result, there is doubt about our ability to continue as a going concern for one year from the issuance date of these financial statements.

 

Off-Balance Sheet Arrangements

 

None.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not applicable.

 

  23  

 

 

Item 4. Controls and Procedures

 

Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) under the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive and financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.

 

As of March 31, 2021, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013 Framework). Based on this assessment, our management concluded that, as of March 31, 2021, our internal control over financial reporting was effective based on those criteria.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting through the date of this report or during the quarter ended March 31, 2021, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

This report does not include an attestation report from our registered public accounting firm regarding internal control over financial reporting.

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

Alpha Capital Anstalt and Brio Capital Master Fund, LTD

 

On September 13, 2017, Alpha Capital Anstalt and Brio Capital Master Fund, LTD, two minority members of a group of investors in the Company (the “Plaintiff”) filed a lawsuit seeking damages and injunctive relief in the United States District Court for the Southern District of New York claiming that the Company breached certain Note and Warrant agreements among the parties to the action. The holders of the majority of the investment involved in the above lawsuit chose not to join in the lawsuit and have informed the Company that they believe the lawsuit to be baseless. On November 21, 2017, the Court denied the Plaintiff’s request for injunctive relief against the Company. As a result, the case essentially became an action for money damages against the Company, which the Company believed to be without merit and defended vigorously. However, on July 27, 2018 United States District Court for the Southern District of New York granted the plaintiffs motion for summary judgement, awarding them approximately $1.4 million dollars. On April 15, 2019 the Company executed a settlement agreement (the “Settlement Agreement”) with the defendants to settle the matter by agreeing to pay the defendants an aggregate of $200,000 and issuing them an aggregate of 7,705,698 of the Company’s common shares (subject to certain possible adjustments to the amount of shares to be issued to the Defendants by the Company). The Company paid this $200,000 to the defendants and issued the 7,705,698 shares to the defendants in the fourth quarter of 2019. Subsequently, the defendant’s claimed the aforementioned share adjustment had been triggered and made a demand that the Company issue additional shares pursuant to the terms of the Settlement. In April 2021, the Company issued an additional aggregate of 2,822,654 shares the Company’s stock to these defendants in final settlement of the dispute.

 

  24  

 

 

Item 1A. Risk Factors

 

Smaller reporting companies are not required to provide the information required by this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

There were no unregistered sales of equity securities during the period covered by this quarterly report.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not Applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

(a) Exhibits

 

EXHIBIT NO.   DESCRIPTION
     
31.1   Section 302 Certification of Chief Executive Officer
31.2   Section 302 Certification of Chief Financial Officer
32.1   Section 906 Certification
32.2   Section 906 Certification
101.INS   XBRL Instance Document
101.SCH   XBRL Taxonomy Extension Schema Document
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document

 

  25  

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

/s/ Bradley J. Yourist   Dated: May 24, 2021
Bradley J. Yourist    
Chief Executive Officer    
     
/s/ Kenneth J. Biehl   Dated: May 24, 2021
Kenneth J. Biehl    
Chief Financial Officer    

 

  26  

Grapefruit USA (QB) (USOTC:GPFT)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Grapefruit USA (QB) Charts.
Grapefruit USA (QB) (USOTC:GPFT)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Grapefruit USA (QB) Charts.